PMID- 18406132
OWN - NLM
STAT- MEDLINE
DCOM- 20080807
LR  - 20211020
IS  - 0959-437X (Print)
IS  - 0959-437X (Linking)
VI  - 18
IP  - 1
DP  - 2008 Feb
TI  - Showering c-MET-dependent cancers with drugs.
PG  - 87-96
LID - 10.1016/j.gde.2008.02.001 [doi]
AB  - The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth 
      factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer 
      therapies. Inappropriate c-MET signaling through autocrine, paracrine, 
      amplification, and mutational activation occurs in virtually all types of solid 
      tumors (http://www.vai.org/met), contributing to one or a combination of 
      proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and 
      HGF/SF participate in all stages of malignant progression and represent promising 
      drug targets in a variety of cancer types, including carcinomas, sarcomas, and 
      brain tumors. While many are in pre-clinical testing, a few inhibitors have 
      entered clinical trials. With hundreds of thousands of potential responding 
      cancers that express c-MET, the interest in this molecule as a drug target is not 
      surprising. However, the cognate c-MET diagnostic tests lag behind. In addition, 
      despite the great enthusiasm based on response rates in phase I trials, there is 
      a need for caution. It is almost without question that combination therapies with 
      c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic 
      tumor response.
FAU - Knudsen, Beatrice S
AU  - Knudsen BS
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 
      Fairview Avenue, Seattle, WA 98109, United States.
FAU - Vande Woude, George
AU  - Vande Woude G
LA  - eng
GR  - P50 CA083636/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080409
PL  - England
TA  - Curr Opin Genet Dev
JT  - Current opinion in genetics & development
JID - 9111375
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Hepatocyte Growth Factor/antagonists & inhibitors
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/drug therapy/enzymology/metabolism
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins c-met/*antagonists & inhibitors/physiology
MH  - Signal Transduction/drug effects
RF  - 110
EDAT- 2008/04/15 09:00
MHDA- 2008/08/08 09:00
CRDT- 2008/04/15 09:00
PHST- 2008/01/22 00:00 [received]
PHST- 2008/02/05 00:00 [accepted]
PHST- 2008/04/15 09:00 [pubmed]
PHST- 2008/08/08 09:00 [medline]
PHST- 2008/04/15 09:00 [entrez]
AID - S0959-437X(08)00026-9 [pii]
AID - 10.1016/j.gde.2008.02.001 [doi]
PST - ppublish
SO  - Curr Opin Genet Dev. 2008 Feb;18(1):87-96. doi: 10.1016/j.gde.2008.02.001. Epub 
      2008 Apr 9.